BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2558871)

  • 1. [Preoperative intensive chemotherapy of operable breast cancer].
    Zhang B
    Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):228-30. PubMed ID: 2558871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myeloid leukemia following cyclophosphamide-containing chemotherapy in a breast cancer patient.
    Porta C; Casagranda I; Semino G; Moroni M; Ratto C
    Haematologica; 1993; 78(1):56-7. PubMed ID: 8387943
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.
    Sataloff DM; Mason BA; Prestipino AJ; Seinige UL; Lieber CP; Baloch Z
    J Am Coll Surg; 1995 Mar; 180(3):297-306. PubMed ID: 7874340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ablative hormone therapy and chemotherapy of metastatic breast cancer].
    Kasch R; Gerber B; Blaschke U
    Zentralbl Gynakol; 1989; 111(23):1584-7. PubMed ID: 2560303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical and histologic effects of preoperative combination chemotherapy of breast cancer].
    Wang ZY
    Zhonghua Wai Ke Za Zhi; 1988 Nov; 26(11):648-50, 700. PubMed ID: 2855506
    [No Abstract]   [Full Text] [Related]  

  • 6. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
    Gianni L; Baselga J; Eiermann W; Guillem Porta V; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Llombart Cussac A; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez Lopez JJ; Mansutti M; Valagussa P; Bonadonna G;
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8715-21. PubMed ID: 16361558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term results of preoperative chemotherapy for operable breast cancer].
    Zhang B; Cai Y; Zhang Q
    Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):277-80. PubMed ID: 11038758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapeutic pathomorphosis of breast cancer].
    Frank GA; Volchenko NN; Borisov VI
    Sov Med; 1990; (11):14-6. PubMed ID: 1963707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.
    Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M
    Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast conservation after induction chemotherapy for locally advanced breast cancer.
    Kling KM; Ostrzega N; Schmit P
    Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
    Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
    J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.
    Rocca A; Peruzzotti G; Ghisini R; Viale G; Veronesi P; Luini A; Intra M; Pietri E; Curigliano G; Giovanardi F; Maisonneuve P; Goldhirsch A; Colleoni M
    Anticancer Drugs; 2006 Nov; 17(10):1201-9. PubMed ID: 17075320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preoperative systemic chemotherapy (FAC) in 3 cases of advanced breast cancer].
    Mizumoto K; Ohyabu H; Ryu S; Jimi M; Ishikawa H; Akashi Y; Miyoshi A; Mawatari Y
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2864-6. PubMed ID: 3755882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early experiences of breast-conservation treatment combined with tamoxifen and CAF chemotherapy for breast cancer of stages I and II.
    Ogawa Y; Nishioka A; Inomata T; Hamada N; Terashima M; Yoshida S; Tanaka Y; Ogoshi S; Araki K; Kumon M
    Radiat Med; 1994; 12(1):29-35. PubMed ID: 8016401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
    Pinder SE; Murray S; Ellis IO; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Gusterson BA
    Cancer; 1998 Oct; 83(8):1529-39. PubMed ID: 9781946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.